China SFDA Vows Quick Action To Prevent Gel-Capsule Scandal Repeat
This article was originally published in PharmAsia News
China’s State FDA spread the word to local authorities to respond quickly and harshly to any reports of unsafe gel capsules found in their areas as part of a long-term monitoring system to prevent a scandal repeat.
You may also be interested in...
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.
In the age of coronavirus, human factors professionals are doing their best to find their way through the pandemic by putting unique twists on usability testing to see what works and what doesn’t in the new reality. That’s the topic of this week’s podcast.